文献速递系统性红斑狼疮

利妥昔单抗治疗系统性红斑狼疮后B细胞清除与重建的单细胞水平特征

Single-Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2026-04-20

该研究对9例接受利妥昔单抗治疗的SLE患者进行纵向单细胞 profiling,并与8例健康对照比较,分析了169,513个免疫细胞。结果显示治疗后早期naïve、记忆和年龄相关B细胞显著清除,后期主要为过渡型B细胞重建;应答者重建的naïve B细胞NF-κB通路活化降低且BAFF-R表面蛋白水平较低。

要点

  • 利妥昔单抗治疗后早期清除naïve、记忆和年龄相关B细胞,后期以过渡型B细胞重建为主。
  • 部分抗原经历B细胞在清除期持续存在,尤其在无应答者中。
  • 应答者重建naïve B细胞的NF-κB通路活化和BAFF-R表面蛋白水平降低。

核心结论

  • 利妥昔单抗治疗后B细胞清除与重建呈现动态变化,应答者与非应答者在抗原经历B细胞持续存在及重建naïve B细胞NF-κB通路活化上存在差异。

研究设计与样本

  • 纵向单细胞 profiling 研究,纳入9例接受利妥昔单抗治疗的SLE患者(治疗前至治疗后15个月)和8例健康对照。
  • 通过单细胞RNA、表面蛋白、B细胞受体(BCR)和T细胞受体测序以及bulk BCR repertoire测序分析了169,513个免疫细胞。

主要发现

  • 治疗后早期naïve、记忆和年龄相关B细胞显著清除,后期主要为过渡型B细胞重建。
  • 部分抗原经历B细胞在清除期持续存在,尤其在无应答者中;早期抗原经历B细胞BCR多样性降低且克隆持续,但未持久。
  • 应答者重建的naïve B细胞NF-κB通路活化降低,与BAFF-R表面蛋白水平较低一致。
  • 非B细胞中鉴定出27个差异表达基因跨7种免疫细胞亚型,调节性CD4 T细胞和双阴性(DN)T细胞变化最多。
  • 应答者CD4 T中央记忆细胞和DN T细胞中细胞毒性、MHC II类抗原呈递和T细胞活化相关基因表达增加。

临床怎么用

  • 利妥昔单抗治疗SLE后可通过监测B细胞亚群重建模式(如过渡型B细胞为主)及抗原经历B细胞持续存在评估应答。
  • 应答者重建naïve B细胞NF-κB通路活化和BAFF-R水平降低,提示BAFF/NF-κB轴可能参与治疗反应机制。

局限性

  • 样本量较小(9例患者和8例对照),结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation. METHODS: We conducted longitudinal single-cell profiling of nine patients with SLE treated with rituximab from pretreatment to up to 15 months post-treatment. These were compared with eight healthy controls. We profiled 169,513 immune cells via single-cell RNA, surface protein, B cell receptor (BCR), and T cell receptor sequencing, and bulk BCR repertoire sequencing. RESULTS: Significant depletion of naïve, memory, and age-associated B cells was observed early post-treatment, followed by later repopulation of mainly transitional B cells. A fraction of antigen-experienced B cells, particularly in nonresponders, persisted through the depletion. BCR repertoire analysis revealed reduced diversity and persistent clones in antigen-experienced cells at early post-treatment, but these effects were not long-lasting. Repopulated naïve B cells in rituximab responders exhibited reduced NF-κB pathway activation, aligning with lower B cell activating factor receptor (BAFF-R) surface protein levels. In non-B cells, we identified 27 differentially expressed genes across seven immune cell subtypes post-rituximab, with regulatory CD4 T cells and double negative (DN) T cells showing the most changes. Responders specifically had increased expression of genes related to cytotoxicity, major histocompatibility complex class II antigen presentation, and T cell activation in CD4 T central memory and DN T cells. CONCLUSION: Our longitudinal profiling provides single-cell resolution of the shifts in immune cell dynamics following B cell depletion.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Jang H, Buang N, Sutherland C, et al. Single-Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2026. PMID: 41787696. doi:10.1002/art.70116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。